-
Phase 1
-
-
20+Age Range
-
Active, Not Recruiting
Active, Not Recruiting
Safety Study of BMS-986016 With or Without Nivolumab in Patients With Advanced Solid Tumors
This study will be used to determine the safety and tolerability of BMS-986016 administered alone and in combination with Nivolumab in subjects with advanced solid tumors.
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable) - Must have received, and then progressed or been intolerant to, standard treatment regimen in the advanced or metastatic setting, if such a therapy exists - Presence of at least one lesion with measurable disease as defined by RECIST v1.1 criteria for response assessment - Males and Females, ages 20 years or older, inclusive Exclusion Criteria: - Known or suspected CNS (central nervous system) metastases or with the CNS as the only site of active disease - Other concomitant malignancies (with some exceptions per protocol) - Any active autoimmune disease or history of known or suspected autoimmune disease - History of uncontrolled or significant cardiovascular disease Other protocol defined inclusion/exclusion criteria could apply
Experimental: Combination Therapy
Experimental: Monotherapy